ATC Group: D06BX02 ฮ™ngenol mebutate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of D06BX02 in the ATC hierarchy

Level Code Title
1 D Dermatologicals
2 D06 Antibiotics and chemotherapeutics for dermatological use
3 D06B Chemotherapeutics for topical use
4 D06BX Other chemotherapeutics
5 D06BX02

Active ingredients in D06BX02

Active Ingredient Description
Ingenol mebutate

Picato is indicated for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults. The mechanism of action of ingenol mebutate for use in actinic keratosis remains to be fully characterised. Results from two clinical studies on biological effects of ingenol mebutate have shown that topical administration induced epidermal necrosis and a profound inflammatory response in both epidermis and the upper dermis of the treated skin, dominated by infiltrating T cells, neutrophils and macrophages.

Related product monographs

Title Information Source Document Type  
PICATO Gel European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Brazil (BR)

Estonia (EE)

Lithuania (LT)

Poland (PL)

Romania (RO)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.